FAC-S                                               carcinoid(37)
 _________________________________________________________________
  fluorouracil.... 400 (300) mg/sqm or

                   [600 (400)] mg/sqm IV days 1 and 8.
  adriamycin...... 30 (15) mg/sqm or

                   [none] mg/sqm IV day 1.
  cytoxan......... 75 (50) mg/sqm/day or

                   [100 (75)] mg/sqm/day orally on days 1 to 14.
  streptozotocin.. 400 (200) mg/sqm or

                   [600 (400)] mg/sqm IV days 1 and 8.
  FREQUENCY....... Repeat cycle every 28 days (4 weeks).


  reference...
    Bukowski RM.  Johnson KG.  Peterson RF.  Stephens RL.  Rivkin 
    SE.  Neilan B. Costanzi JH. A phase II trial of combination 
    chemotherapy in patients with metastatic carcinoid tumors. A 
    Southwest Oncology Group Study. Cancer.  60(12):2891-5, 1987 
    Dec 15. 
  abstract...
    A prospective Phase II trial of combination chemotherapy in 
    patients with metastatic carcinoid tumors was conducted by the 
    Southwest Oncology Group. The therapy included 5-fluorouracil, 
    Adriamycin, cyclophosphamide, and streptozotocin (FAC-S) or 
    the same combination without Adriamycin (FC-S) in patients 
    with heart disease. Seventy-four patients were entered and two 
    were ineligible. Sixty-nine of the 72 were histologically 
    reviewed. Six patients were declared ineligible after this 
    review. Fifty-six patients received FAC-S, and nine received 
    FC-S (one patient was inevaluable). The response rates were 
    31% and 22%, respectively. The median survival of all patients 
    was 10.8 months. The analyses of various clinical and 
    histologic parameters indicated that responses were more 
    common in patients with gastrintestinal carcinoids; there was 
    also a tendency toward shorter survival in patients with 
    tumors that had a higher mitotic rate or the atypical and/or 
    undifferentiated histologic pattern. The FAC-S combination can 
    produce objective responses in patients with metastatic 
    carcinoid tumors, but these are generally partial and brief. 
    It was also concluded that currently available chemotherapy is 
    inadequate.